Welcome to GCCN
Global Cancer coalitions Network
Representing close to 775+ cancer patient advocacy and support organisations who are working on behalf of over 14 million patients around the world.
About us
Working Together
Established in May 2020 in response to concerns about the impact of COVID-19 on member organisations, the Global Cancer Coalitions Network collectively represents over 775+ cancer patient advocacy and support organisations who are working on behalf of over 14 million patients around the world. The network came together to share experiences and best practice, a process they have found invaluable during the pandemic, and one that they plan to continue.
For our full Terms of Reference click here.
Our Members
Our Past Successes
Since coming together in 2020, the GCCN has completed two surveys looking at the impact of the pandemic on our member organizations, the patients they support and cancer services. Both of the reports were widely covered in global cancer publications and formed the basis of a number of abstracts. Most of our GCCN members have also presented the findings from this work within their own networks and presented the findings and a number of events and congresses. We also ran a successful series of webinars around key issues raised by this work.
Through both in-person and virtual meetings, GCCN has strengthened our coalition members through the sharing of best practices, educational and engagement opportunities and tracking global trends.
Latest webinar
Coalition Connection 3: Sustaining Patient Advocacy Post-COVID
Many patient advocacy organizations faced extraordinary challenges during the COVID-19 pandemic, from loss of crucial funding to significant reductions in human resources, both paid and unpaid.
As we look to a post-pandemic future, at this free GCCN event we will hear three perspectives from the advocacy world on how they coped with those challenges, what ‘silver linings’ they found, and how out of the box thinking was adopted in the face of this global health crisis- and ultimately what can be taken away as lessons learned as we transition to the new ‘new normal’.
A live Q&A will follow and registrants can pose initial questions upon registration.
Past Activities and events
Coalition Connection 2: COVID-19 Vaccines & Cancer
The COVID19 vaccine rollout has presented many challenges, not least of which for those already coping with a cancer diagnosis.On November 23rd, the GCCN held a free Cancer and COVID19 Vaccine event that aimed to answer audience questions from the perspectives of an Immunologist, Haematologist, Oncologist, and Psychologist. We also highlighted examples of good practice from our members around the world in this interactive event.
Past Activities and events
Coalition Connection:
Effects of COVID-19
World Cancer Day 2021
On World Cancer Day, February 4, 2021, members of the cancer community from around the world joined us for the inaugural Coalition Connection event. Examining the effects of COVID-19 and innovative strategies that patient advocacy organizations employed in the wake of the pandemic, this event featured a combination of keynote speakers and panel discussions that looked at the following:
- On the Ground Data: results from the GCCN survey of patient organizations on the impact of COVID-19
- Consequences of Isolation: the psycho-social impact of pandemic related isolation
- New communication methods: the value and drawbacks of new and innovative communication approaches developed during COVID-19
PUBLICATIONS AND ABSTRACTS
COVID-19: Impact on Cancer Patient Organisations
In 2020 we asked our partner organisations to participate in an initial and follow-up COVID-19 impact surveys. We are happy to share the final results here.
Released on World Cancer Day during the GCCN Coalition Connection inaugural event on COVID-19, the survey results show that patient advocacy organisations are facing a clear and present danger with few signs of reprieve as the pandemic continues.
Sponsorship
The Global Cancer Coalitions Network recognises the generous support of AstraZeneca and Exelixis in support of our independent activities. The GCCN retains the editorial control and independence of all its activities